Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 6
1992 39
1993 42
1994 66
1995 76
1996 86
1997 77
1998 71
1999 78
2000 71
2001 51
2002 32
2003 40
2004 35
2005 37
2006 42
2007 38
2008 44
2009 40
2010 50
2011 55
2012 53
2013 45
2014 39
2015 63
2016 54
2017 41
2018 42
2019 33
2020 44
2021 35
2022 33
2023 40
2024 13
2025 32
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,542 results

Results by year

Filters applied: . Clear all
Page 1
Icatibant for hereditary angioedema.
Gras J. Gras J. Drugs Today (Barc). 2009 Dec;45(12):855-64. doi: 10.1358/dot.2009.45.12.1424267. Drugs Today (Barc). 2009. PMID: 20135020 Review.
Recently, it has been demonstrated that bradykinin (BK) is responsible for most of the symptoms of HAE. Icatibant (Firazyr, HOE 140, JE049) is a potent, specific and selective B2 BK receptor antagonist that has recently been approved by the EMEA for the treatment of …
Recently, it has been demonstrated that bradykinin (BK) is responsible for most of the symptoms of HAE. Icatibant (Firazyr, HO …
Icatibant.
Deeks ED. Deeks ED. Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000. Drugs. 2010. PMID: 20030426
Icatibant is a selective antagonist of the bradykinin type 2 receptor. In the randomized, double-blind, multicentre, FAST-1 trial, the difference in the median time to the onset of symptom relief (primary endpoint) did not reach statistical significance between a single do …
Icatibant is a selective antagonist of the bradykinin type 2 receptor. In the randomized, double-blind, multicentre, FAST-1 trial, th …
Icatibant in viral infections.
Mustonen J, Antonen J, Vaheri A. Mustonen J, et al. Infect Dis (Lond). 2023 Jun;55(6):444-445. doi: 10.1080/23744235.2023.2200563. Epub 2023 Apr 17. Infect Dis (Lond). 2023. PMID: 37067851 No abstract available.
The Angiotensin-Converting-Enzyme-Induced Angioedema.
Bas M. Bas M. Immunol Allergy Clin North Am. 2017 Feb;37(1):183-200. doi: 10.1016/j.iac.2016.08.011. Immunol Allergy Clin North Am. 2017. PMID: 27886906 Review.
The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug is not approved officially for this indication and has to be administered in an emergency situation off-label. ...
The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug …
Icatibant.
Dubois EA, Cohen AF. Dubois EA, et al. Br J Clin Pharmacol. 2010 May;69(5):425-6. doi: 10.1111/j.1365-2125.2010.03642.x. Br J Clin Pharmacol. 2010. PMID: 20573077 Free PMC article. No abstract available.
ACE inhibitor-mediated angioedema.
Montinaro V, Cicardi M. Montinaro V, et al. Int Immunopharmacol. 2020 Jan;78:106081. doi: 10.1016/j.intimp.2019.106081. Epub 2019 Dec 10. Int Immunopharmacol. 2020. PMID: 31835086 Review.
Interventional studies with the specific bradykinin receptor antagonist icatibant have shown conflicting results; there might be a different ethnic predisposition to icatibant efficacy which has been proven in caucasian but not in black patients....
Interventional studies with the specific bradykinin receptor antagonist icatibant have shown conflicting results; there might be a di …
The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M, Aberer W, Caballero T, Bouillet L, Grumach AS, Botha J, Andresen I, Longhurst HJ; IOS Study Group. Maurer M, et al. Clin Exp Allergy. 2022 Sep;52(9):1048-1058. doi: 10.1111/cea.14206. Epub 2022 Aug 7. Clin Exp Allergy. 2022. PMID: 35861129 Review.
In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B(2) receptors. Icatibant, a selective bradykinin B(2) receptor antagonist, is approved for on-demand treatment of HAE attacks. The Icatibant Outcome Survey (I …
In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B(2) receptors. Icatibant, …
Icatibant for the treatment of hereditary angioedema.
Cole SW, Lundquist LM. Cole SW, et al. Ann Pharmacother. 2013 Jan;47(1):49-55. doi: 10.1345/aph.1R423. Epub 2012 Dec 18. Ann Pharmacother. 2013. PMID: 23249729 Review.

When icatibant was compared to tranexamic acid in FAST-2, the median time to clinically significant relief of the index symptom was shorter for patients receiving icatibant (p < 0.001). The most common adverse events associated with the administration of icati

…
When icatibant was compared to tranexamic acid in FAST-2, the median time to clinically significant relief of the index symptom was s …
Management of acute attacks of hereditary angioedema: potential role of icatibant.
Longhurst HJ. Longhurst HJ. Vasc Health Risk Manag. 2010 Sep 7;6:795-802. doi: 10.2147/vhrm.s4332. Vasc Health Risk Manag. 2010. PMID: 20859548 Free PMC article. Review.
Icatibant (Firazyr( )) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioedema. Hereditary angioedema, resulting from inherited partial C1 inhibitor deficiency, is a disabling condition characterized by intermittent …
Icatibant (Firazyr( )) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioede …
Reply.
Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J, Schranz J, Baptista J, Kimura A, Nothaft W; CAMEO study group. Sinert R, et al. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1803-1804. doi: 10.1016/j.jaip.2017.07.040. J Allergy Clin Immunol Pract. 2017. PMID: 29122164 Free article. No abstract available.
1,542 results